Project Grant R43TR005426
Award Date
7/1/25
Completion Date
6/30/26
Dollars Obligated
$305K
Federal Agency
National Center for Advancing Translational Sciences
Federal Grant Program
93.350
Assistance Type
Project Grant
Place of Performance
New Jersey, USA
Similar Awards
The National Center for Advancing Translational Sciences (NCATS), under CFDA 93.350, has awarded a $324,962 Project Grant to Tetmedical, Inc. to develop a technology for rapid, point-of-care and at-home testing of liver enzyme levels. The goal is to enable convenient and timely monitoring of drug-induced liver injury (DILI) and other sources of liver damage. The project aims to optimize tethered enzyme assays for detecting aspartate aminotransferase (AST) and alanine aminotransferase (ALT),...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $2,095,816 Project Grant under the Cardiovascular Diseases Research (CFDA 93.837) program to The DNA Medicine Institute, Inc. to develop a 5-minute point-of-care test for measuring anti-Factor Xa activity and hemoglobin levels. This diagnostic device is intended to guide emergent management of bleeding and strokes in patients on anti-Xa direct oral anticoagulants. The award period runs from September 10, 2024 to August 31, 2026. The...
This $265,347 Project Grant awarded by the National Heart Lung and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) supports the development and initial validation of a point-of-care device by Functional Fluidics Inc. to assess red blood cell sickling in patients with sickle cell disease. The goal is to create a simple, stand-alone, and potentially CLIA-waived diagnostic system that can be used to monitor patient condition and treatment response, especially for drugs affecting...
This Project Grant award of $542,442.00 from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) to Emory University aims to develop a new diagnostic technology named MCATS (Mechano-Assisted CAS12A Tension Sensor) to rapidly and accurately detect Heparin-Induced Thrombocytopenia (HIT). The central hypothesis is that the mechanical forces generated by platelets can serve as a physical biomarker for diagnosing HIT, which currently requires complex and...
The National Center for Advancing Translational Sciences (NCATS) awarded a $275,000 Project Grant (CFDA 93.350) to Nectagen Inc. to develop bioprocess-compatible, second-generation nanoclamp affinity resins for the efficient purification of plasma-based therapeutic proteins. The goal is to identify panels of nanoclamps to 5 industrially relevant plasma-based therapeutics, select lead candidates, and optimize the resins for maximum recovery and purity from plasma samples. This project aims to...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $321,363 to Nucleusrx, Inc. to develop and test a virtual care platform and remote intervention tool targeting post-acute care heart failure (HF) patients. The goal is to create a solution that enables healthcare providers to implement a safe discharge transition plan from hospital to home, while allowing rapid optimization of...
The federal Project Grant award SB1HD116629, provided by the National Institute of Child Health and Human Development (NICHD) under the Child Health and Human Development Extramural Research program (CFDA 93.865), supports the development of a home-based device to accurately measure metabolite levels in individuals with rare metabolic disorders. Sequitur Health Corp, a for-profit company located in Scottsdale, Arizona, received $1,000,000.00 to perform late-stage development and...
The National Institute of Child Health and Human Development (NICHD) awarded a $624,998 Project Grant under the Child Health and Human Development Extramural Research program (CFDA 93.865) to Giner Inc., a small business in Auburndale, Massachusetts. The grant will support the development and validation of an electrochemical assay and point-of-care (POC) instrument for highly sensitive and rapid measurement of oxytocin levels. Oxytocin is a critical hormone involved in childbirth, postpartum...
The federal Project Grant award R43HL177857, totaling $306,101.00, was provided by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837). The grant aims to develop a novel, non-invasive urinary biomarker assay that can predict the development of cardiovascular disease (CVD) earlier and with greater accuracy than the current standard of microalbuminuria. The project will focus on standardizing the assay and conducting a pilot...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $297,587 Project Grant (CFDA 93.837 - Cardiovascular Diseases Research) to General Fluidics Corporation to validate the performance of the AXESS system, a novel point-of-need clinical chemistry and hematology platform. The goal is to demonstrate equivalence between the AXESS system's results and those obtained from standard venous blood testing for a basic metabolic panel and complete blood count, using matched capillary and...